Abnormal phosphorylation of Tau protein (such as p-tau181, p-tau231) is a typical marker of Alzheimer’s disease (AD), and elevated CSF Tau levels are also observed in PD-MCI patients; however, its pathological distribution and clinical significance differ from those in AD-MCI. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.